AR070813A1 - Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1 - Google Patents
Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1Info
- Publication number
- AR070813A1 AR070813A1 ARP090100803A ARP090100803A AR070813A1 AR 070813 A1 AR070813 A1 AR 070813A1 AR P090100803 A ARP090100803 A AR P090100803A AR P090100803 A ARP090100803 A AR P090100803A AR 070813 A1 AR070813 A1 AR 070813A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl group
- different
- alkoxy
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Composicion farmacéutica que los contiene, junto con un vehículo farmacéuticamente aceptable, y a su utilizacion en un método para tratar o prevenir enfermedades basadas en la expresion de MCP-1 y CX3CR1, como enfermedades cardiovasculares, articulares, obesidad, diabetes, cáncer. Reivindicacion 1: Compuesto de formula (1) en la que: A puede ser -X1- o -X1-O-X2-, en los que X1 puede ser un grupo alquilo C1-5, opcionalmente sustituido con uno o más grupos alquilo C1-5 o uno o más grupos alcoxi C1-3, y X2 puede ser un grupo alquilo C1-5, opcionalmente sustituido con uno o más grupos alquilo C1-5, Y puede ser hidrogeno, -OH, -N(R11)(R12), -N(R11)O(R12), en los que R11 puede ser hidrogeno, un grupo alquilo C1-5, alcoxi C1-3, o R11 junto con R12 forma un heterociclo de 4 a 7 miembros, R12 puede ser hidrogeno, un grupo alquilo C1-5, alcoxi C1-3, arilo, heteroarilo, alquilarilo, alquilheteroarilo, COR', COOR', CON(R')(Rö), con R' y Rö, que pueden ser idénticos o diferentes entre sí, representados por hidrogeno y un grupo alquilo C1-5, o R12 junto con R11 forma un heterociclo de 4 a 7 miembros, R1 y R2, que pueden ser idénticos o diferentes entre sí, pueden ser hidrogeno, un grupo alquilo C1-5, R3, R4 y R8, que pueden ser idénticos o diferentes entre sí, pueden ser hidrogeno, un grupo alquilo C1-5, alcoxi C1-3, un átomo de halogeno, -OH, -N(R')(Rö), -N(R')CORö, -CN, -CONR'Rö, -SO2NR'Rö, -SO2R', nitro y trifluorometilo; con R' y Rö, que pueden ser idénticos o diferentes entre sí, representados por hidrogeno y un grupo alquilo C1-5, R5 puede ser hidrogeno, un grupo alquilo C1-5, alcoxi C1-3, un átomo de halogeno, -OH, -N(R')(Rö), -N(R')CORö, nitro y trifluorometilo, o R5 junto con uno de entre R6 y R7 forma un anillo que presenta 5 o 6 átomos de carbono; con R' y Rö, que pueden ser idénticos o diferentes entre sí, representados por hidrogeno y un grupo alquilo C1-5, R6 y R7, que pueden ser idénticos o diferentes entre sí, pueden ser hidrogeno, un grupo alquilo C1-5, o forman conjuntamente un grupo C=O, o uno de entre R6 y R7, junto con R5, forma un anillo que presenta 5 o 6 átomos de carbono.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425141 | 2008-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070813A1 true AR070813A1 (es) | 2010-05-05 |
Family
ID=39672135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100803A AR070813A1 (es) | 2008-03-07 | 2009-03-06 | Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8314099B2 (es) |
| EP (1) | EP2262777B8 (es) |
| JP (1) | JP5509102B2 (es) |
| KR (1) | KR101581829B1 (es) |
| CN (1) | CN101959866B (es) |
| AR (1) | AR070813A1 (es) |
| AU (1) | AU2009221063B2 (es) |
| BR (1) | BRPI0908883A2 (es) |
| CA (1) | CA2715065C (es) |
| CY (1) | CY1117504T1 (es) |
| DK (1) | DK2262777T3 (es) |
| EA (1) | EA018185B1 (es) |
| ES (1) | ES2570766T3 (es) |
| GE (1) | GEP20135913B (es) |
| HK (1) | HK1148271A1 (es) |
| HR (1) | HRP20160457T1 (es) |
| HU (1) | HUE026910T2 (es) |
| IL (1) | IL207278A (es) |
| MX (1) | MX2010009624A (es) |
| PL (1) | PL2262777T3 (es) |
| SI (1) | SI2262777T1 (es) |
| UA (1) | UA101350C2 (es) |
| WO (1) | WO2009109654A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5509099B2 (ja) * | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体並びにそのＭＣＰ−１、ＣＸ３ＣＲ１およびｐ４０の発現に基づく疾患の治療への使用 |
| US8461194B2 (en) * | 2008-03-07 | 2013-06-11 | Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 |
| UA108742C2 (uk) | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| TWI543975B (zh) * | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| CA2874919A1 (en) * | 2012-06-01 | 2013-12-05 | Nogra Pharma Limited | Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| JP5872105B2 (ja) * | 2013-03-12 | 2016-03-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン−３−イル酢酸誘導体の塩およびその結晶 |
| WO2014142086A1 (ja) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体 |
| EP3310353A4 (en) * | 2015-06-16 | 2019-02-06 | Translatum Medicus, Inc. | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES |
| EP3990433A4 (en) * | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| IT1253703B (it) | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| IT1293795B1 (it) | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| MXPA06003792A (es) | 2003-10-07 | 2006-06-14 | Astrazeneca Ab | Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1. |
| US20070043057A1 (en) * | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| JP5509099B2 (ja) * | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体並びにそのＭＣＰ−１、ＣＸ３ＣＲ１およびｐ４０の発現に基づく疾患の治療への使用 |
| US8461194B2 (en) | 2008-03-07 | 2013-06-11 | Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 |
| UA108742C2 (uk) | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 |
-
2009
- 2009-03-06 BR BRPI0908883A patent/BRPI0908883A2/pt not_active IP Right Cessation
- 2009-03-06 JP JP2010549159A patent/JP5509102B2/ja not_active Expired - Fee Related
- 2009-03-06 EA EA201071043A patent/EA018185B1/ru not_active IP Right Cessation
- 2009-03-06 GE GEAP200911966A patent/GEP20135913B/en unknown
- 2009-03-06 ES ES09718101T patent/ES2570766T3/es active Active
- 2009-03-06 CA CA2715065A patent/CA2715065C/en not_active Expired - Fee Related
- 2009-03-06 SI SI200931403A patent/SI2262777T1/sl unknown
- 2009-03-06 US US12/866,814 patent/US8314099B2/en not_active Expired - Fee Related
- 2009-03-06 AR ARP090100803A patent/AR070813A1/es not_active Application Discontinuation
- 2009-03-06 MX MX2010009624A patent/MX2010009624A/es active IP Right Grant
- 2009-03-06 KR KR1020107019966A patent/KR101581829B1/ko not_active IP Right Cessation
- 2009-03-06 PL PL09718101T patent/PL2262777T3/pl unknown
- 2009-03-06 AU AU2009221063A patent/AU2009221063B2/en not_active Ceased
- 2009-03-06 EP EP09718101.0A patent/EP2262777B8/en active Active
- 2009-03-06 CN CN2009801074866A patent/CN101959866B/zh not_active Expired - Fee Related
- 2009-03-06 WO PCT/EP2009/052660 patent/WO2009109654A2/en active Application Filing
- 2009-03-06 HU HUE09718101A patent/HUE026910T2/en unknown
- 2009-03-06 DK DK09718101.0T patent/DK2262777T3/en active
- 2009-06-03 UA UAA201009900A patent/UA101350C2/uk unknown
-
2010
- 2010-07-29 IL IL207278A patent/IL207278A/en not_active IP Right Cessation
-
2011
- 2011-03-07 HK HK11102288.4A patent/HK1148271A1/zh not_active IP Right Cessation
-
2012
- 2012-09-14 US US13/618,948 patent/US8569297B2/en not_active Expired - Fee Related
-
2016
- 2016-04-28 HR HRP20160457TT patent/HRP20160457T1/hr unknown
- 2016-05-13 CY CY20161100407T patent/CY1117504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070813A1 (es) | Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1 | |
| AR070811A1 (es) | Derivados de 1- bencil-3- hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40 | |
| AR070812A1 (es) | Derivados de 1- bencil-3- hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40 | |
| EA201490491A1 (ru) | Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2 | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR069364A1 (es) | Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR059314A1 (es) | Derivados de las benzamidas y heteroarenos | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| PE20130339A1 (es) | Compuestos heterociclicos y sus usos | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| MX338114B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| UY32662A (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| BR112014027359A2 (pt) | moduladores da série de reação complementar e usos dos mesmos | |
| PE20150289A1 (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| UY31159A1 (es) | Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos | |
| UY31712A1 (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen | |
| AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
| CY1119296T1 (el) | Ενωση δικαρβοξυλικου οξεος |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |